Laureen Debuono - Dec 16, 2024 Form 4 Insider Report for Rani Therapeutics Holdings, Inc. (RANI)

Role
Director
Signature
Svai Sanford. Attorney-in-Fact for Laureen DeBuono
Stock symbol
RANI
Transactions as of
Dec 16, 2024
Transactions value $
$0
Form type
4
Date filed
12/17/2024, 05:00 PM
Previous filing
May 30, 2024

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction RANI Stock Option (Right to Buy) Disposed to Issuer -101K -100% 0 Dec 16, 2024 Class A Common Stock 101K $2.84 Direct F1
transaction RANI Stock Option (Right to Buy) Award +101K 101K Dec 16, 2024 Class A Common Stock 101K $4.11 Direct F1
transaction RANI Stock Option (Right to Buy) Disposed to Issuer -18.9K -100% 0 Dec 16, 2024 Class A Common Stock 18.9K $2.84 Direct F2, F3
transaction RANI Stock Option (Right to Buy) Award +18.9K +16.13% 136K Dec 16, 2024 Class A Common Stock 18.9K $9.44 Direct F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 On December 16, 2024, the exercise price of the stock options has been amended to increase the exercise price to $4.11 per share. There is no change to the expiration dates or the vesting schedule of the options.
F2 The shares subject to the option vested as follows: 1/3rd of the shares subject to the option vested on April 20, 2022; and 1/36th of the shares subject to the option vested monthly over the following two years.
F3 On December 16, 2024, the exercise price of the stock options has been amended to increase the exercise price to $9.44 per share. There is no change to the expiration dates or the vesting schedule of the options.